-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Ono Pharmaceuticals of Japan recently announced that it has filed a listing application for ONO-7643, a gastric hunger agent (ghrelin) permutation agent used to improve weight loss and anorexia in patients with cancer.
The application is based on the results of two clinical studies conducted in Japan in patients with cancer erythroid disease: (1) a multi-center, placebo-controlled, randomized, double-blind, parallel group study (ONO-ONO-) in patients with non-small cell lung cancer (NSCLC). 7643-04 Study) ;(2) A multi-center, open-label, non-controlled Phase III study (ONO-7643-05 study) in patients with colorectal, stomach and pancreatic cancers.
study, anamorelin showed weight gain, muscle mass, and appetite in cancer patients. It is worth mentioning that anamorelin was one of the most important innovations in oncology in 2014 by the judges of the European Association Technology Association (ASCO). If approved, anamorelin is expected to be the first drug to treat cancer.
cancer is a complex metabolic disorder characterized by weight loss (especially muscle mass loss) and cancer-related anorexia. Cancer can have a significant negative impact on the quality of life and prognosis of patients. To date, no effective treatment has been established.anamorelin molecular structure
anamorelin is a new, oral, selective gastric hunger agent (ghrelin) permitation agent. Gastric hunger hormone is an endogenemic peptide, mainly secreted by the stomach, combined with its subject, stimulates a variety of ways to positively regulate weight, muscle mass, appetite and metabolism. By simulating stomach hunger hormone secreted by the gastrointestinal tract, anamorelin can improve weight loss and loss of appetite in patients with cancer.
under a licensing agreement with Helsinn Healthcare SA, a subsidiary of the Swiss Helsinn Group, Ono Pharmaceuticals has exclusive rights to the development and commercialization of Anamorelin in Japan, Korea and Taiwan, China. (Bio Valley)
